Knowledge Hub

Billions Invested in Research and Development to Prove Beneficial for Global mRNA Vaccines and Therapeutics Market

Press Release   •   Aug 22, 2017 06:05 EDT has added a new report to its repository, titled, “Global mRNA Vaccines & Therapeutics Market Research Report 2017.” It offers a complete study with detailed reports of historical market performance, present trends, and future prospects of the market across the world.

Messenger RNA (mRNA) is a naturally occurring molecule that transfers genetic information from the DNA to the ribosome, where they specify the amino acid sequence of the protein products of gene expression. mRNA is slated to revolutionize the biopharmaceutical industry. However, for a long time messenger RNA (mRNA) was considered a poor therapeutic agent because of its comparatively lesser half-life and its immunogenicity. Its versatility and other advantages were ignored, largely.
mRNA does not have genomic integration and its use results in transient expression of the encoded protein. This helpful safety profile makes mRNA particularly suited for vaccines and gene editing. Further, mRNA is well defined chemically and this enables reproducible manufacturing at high yield and purity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has proved highly beneficial for the development of in vivo transfection strategies.
Get Sample Copy Of This Report @

The report throws light into the key geographic segments in the global mRNA vaccines and therapeutics market which are Europe, North America, Japan, China, India, and Southeast Asia. Depending upon the type of product, the report segments the market into standardization of cancer treatment MRNA vaccine, individualized cancer treatment MRNA vaccine, infectious disease treatment MRNA vaccine, and infection prevention MRNA vaccine. The report discusses their production processes, the revenue each segment rakes in, their price and market share, and their growth too.
The report also discusses the mRNA vaccine and therapeutic pipelines and important stakeholders in the field, particularly technology companies, rare disease biopharma companies, and major pharmaceutical companies. The report highlights the value of mRNA vaccines and therapeutics in terms of partnering economic condition and equity financing rounds.
Billions have been poured into mRNA technologies through equity financing and frontloaded partnership payments. In addition, billion have also been invested in research and development and potential milestone payments. A noticeable trend in the global mRNA vaccines market is a clutch of prominent pharmaceutical and rare disease specialist biopharmaceutical companies collaborating with mRNA technology companies. So far, at least 16 mRNA vaccines and therapeutics are in clinical stages and quite a few are in the pre-IND or IND stage.
View Press Release @
Some of the key players in the global mRNA vaccines and therapeutics market, profiled in the report are Argos Therapeutics, Bayer, AstraZeneca, BioNTech, Boehringer Ingelheim, CureVac, CRISPR Therapeutics, Ethris, eTheRNA Immunotherapies, In-Cell-Art, GlaxoSmithKline Vaccines, Kernal Biologics, Novartis, Intellia Therapeutics, Moderna Therapeutics, Janssen, MaxCyte, PhaseRx, RaNa Therapeutics, and Precision NanoSystems. The report examines their product portfolios and sales and revenues. It also studies their market shares and prospects going forward.